Research Article
Survival Outcomes among Human Epidermal Growth Factor Receptor 2- (HER2-) Positive Breast Cancer Patients at Kenyatta National Hospital
Table 3
Treatment regimen administered to the HER2-positive breast cancer patients.
| Variable | Frequency | Percent |
| Treatment regimen for early-stage disease | | | Radiotherapy | 8 | 25 | Chemotherapy | 11 | 34.4 | Surgery | 10 | 31.3 | Trastuzumab | 3 | 9.3 | Treatment regimen for the incurable disease | | | Radiotherapy | 6 | 33.3 | Chemotherapy | 11 | 61.1 | Trastuzumab | 1 | 5.6 |
|
|